Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Naomi Sugimura"'
Autor:
Naomi Sugimura, Eiji Kubota, Makiko Sasaki, Shigeki Fukusada, Yusuke Mizuno, Hiroyasu Iwasaki, Mamoru Tanaka, Keiji Ozeki, Takaya Shimura, Hiromi Kataoka
Publikováno v:
DEN Open, Vol 4, Iss 1, Pp n/a-n/a (2024)
Abstract Plexiform fibromyxoma is a rare mesenchymal tumor identified in recent years and presents as a gastrointestinal submucosal tumor that is typically located in the gastric antrum. We report a case of gastric plexiform fibromyxoma in which the
Externí odkaz:
https://doaj.org/article/60d9d90701b1413f9cc04a7fc1922645
Autor:
Takaya Shimura, MD, PhD, Naomi Sugimura, MD, PhD, Hiroyasu Iwasaki, MD, PhD, Takahito Katano, MD, PhD, Hiromi Kataoka, MD, PhD
Publikováno v:
VideoGIE, Vol 7, Iss 2, Pp 65-67 (2022)
Externí odkaz:
https://doaj.org/article/e19140bf58954b819156c75bbf02f9cb
Autor:
Taketo Suzuki, Tsutomu Mizoshita, Satoshi Tanida, Naomi Sugimura, Takahito Katano, Hirotada Nishie, Hiromi Kataoka
Publikováno v:
JGH Open, Vol 3, Iss 3, Pp 217-223 (2019)
Background and Aim Tacrolimus (TAC) is an important therapeutic option for remission induction in patients with refractory ulcerative colitis (UC). However, there is little evidence available on long‐term outcomes and maintenance treatments after T
Externí odkaz:
https://doaj.org/article/9f613da257ad4589b85f16269608c38c
Autor:
Taketo Suzuki, Tsutomu Mizoshita, Tomoya Sugiyama, Yoshikazu Hirata, Yoshihide Kimura, Yuka Suzuki, Tomonori Yamada, Hironobu Tsukamoto, Takashi Mizushima, Naomi Sugimura, Takahito Katano, Satoshi Tanida, Hiromi Kataoka, Makoto Sasaki
Publikováno v:
Case Reports in Gastroenterology, Vol 13, Iss 1, Pp 37-49 (2019)
Background/Aims: Adalimumab dose escalation is one of the most important options in refractory Crohn’s disease patients with loss of response to adalimumab. The goal of this study was to evaluate the effectiveness of adalimumab dose escalation in C
Externí odkaz:
https://doaj.org/article/003724b9516e4742b67eccd609200e7a
Autor:
Yusuke Okuda, Takaya Shimura, Konomu Uno, Tomonori Yamada, Takayuki Nukui, Takashi Mizushima, Yuya Takenaka, Keisuke Itoh, Yuki Inagaki, Takanori Ozeki, Kazuhiro Nagao, Masahide Ebi, Erika Uchida, Satoshi Nomura, Yu Nojiri, Shozo Togawa, Naomi Sugimura, Shigeki Fukusada, Hiroyasu Iwasaki, Takahito Katano, Hiromi Kataoka
Publikováno v:
Journal of Gastroenterology. 58:217-228
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b552f209f97d52d4a5b18cc3ba598b37
https://doi.org/10.1007/s00535-022-01952-x
https://doi.org/10.1007/s00535-022-01952-x
Autor:
Eiji Kubota, Naomi Sugimura, Yoshinori Mori, Mineyoshi Aoyama, Mamoru Tanaka, Takaya Shimura, Satoshi Tanida, Randal Johnston, Hiromi Kataoka
Reovirus, a naturally occurring oncolytic virus, initiates the lysis of tumor cells while simultaneously releasing tumor antigens or proapoptotic cytokines in the tumor microenvironment to augment anticancer immunity. However, reovirus has developed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::300b1bdab1d8ccfb6928c835ed8e2959
https://doi.org/10.21203/rs.3.rs-2251036/v1
https://doi.org/10.21203/rs.3.rs-2251036/v1
Autor:
Satoshi Tanida, Keiji Ozeki, Takuya Kanno, Takahito Katano, Naomi Sugimura, Hirotada Nishie, Hiroyasu Iwasaki, Mamoru Tanaka, Takaya Shimura, Eiji Kubota, Hiromi Kataoka
Publikováno v:
Journal of Clinical Medicine Research
There are currently no reports on the efficacy and safety of combination therapy with ustekinumab (UST) plus intensive granulocyte and monocyte adsorptive apheresis (GMA) for the treatment of refractory ulcerative colitis (UC). We retrospectively eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e927f4982d5acb68b73f3f76d1f0c28
http://europepmc.org/articles/PMC8670766
http://europepmc.org/articles/PMC8670766
Autor:
Takaya Shimura, Tomotaka Okubo, Hiromi Kataoka, Naomi Sugimura, Hiroyasu Iwasaki, Takahito Katano, Yusuke Okuda
Publikováno v:
Endoscopy. 54(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c32608147f3698c938062eec9cf2b798
https://pubmed.ncbi.nlm.nih.gov/34695848
https://pubmed.ncbi.nlm.nih.gov/34695848
Autor:
Satoshi Tanida, Tsutomu Mizoshita, Taketo Suzuki, Hiromi Kataoka, Makoto Sasaki, Naomi Sugimura, Tomokatsu Miyaki, Shozo Togawa, Tomoya Sugiyama
Publikováno v:
Digestive and Liver Disease. 51:967-971
Background Anti-tumor necrosis factor-α agents are important for managing refractory intestinal Behcet’s disease. Few studies have reported the efficacy of anti-tumor necrosis factor-α monoclonal antibodies for intestinal Behcet’s disease due t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a8dacc87f8f246d1ead93fce5701c0c
https://doi.org/10.1016/j.dld.2018.10.024
https://doi.org/10.1016/j.dld.2018.10.024
Autor:
Satoshi Tanida, Naomi Sugimura, Hiromi Kataoka, Hirotada Nishie, Taketo Suzuki, Takahito Katano, Tsutomu Mizoshita
Publikováno v:
JGH Open: An Open Access Journal of Gastroenterology and Hepatology
JGH Open, Vol 3, Iss 3, Pp 217-223 (2019)
JGH Open, Vol 3, Iss 3, Pp 217-223 (2019)
Background and aim Tacrolimus (TAC) is an important therapeutic option for remission induction in patients with refractory ulcerative colitis (UC). However, there is little evidence available on long-term outcomes and maintenance treatments after TAC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d0402953706ca03dfd95467e33f8489
http://europepmc.org/articles/PMC6586576
http://europepmc.org/articles/PMC6586576